Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis

Naval Military Medical University

Status: Enrolling

Conditions: Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases

Study type: Observational

Funder types: Other

Identifiers

NCT05183425

CHCS-PDO

Details and patient eligibility

About

Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven colorectal cancer with liver metastasis
• Aged between 18 and 70 years
• Written informed and signed consent
• Accessible to surgery sample of metastasis and primary tumor

Exclusion criteria

• Less than 18 years and older than 70 years
• Not able to give informed consent
• Not accessible to surgery sample